BIRC5 and hepatocellular carcinoma: Lu et al. (133) reported that AD targets BIRC5 and FEN1, genes closely linked to immune modulation, producing substantial anticancer effects in HCC patients via the combined action of cantharidin, formononetin, and isofraxidin.